Swedish life science tools company Mabtech announced on Wednesday a strategic collaboration with Sai Life Sciences, a global Contract Research Organisation (CRO).

Under the agreement, Sai's Boston discovery laboratory will serve as a co-marketed US execution and demonstration hub for Mabtech's EYRA multiplex immunology platform.

The collaboration will see Mabtech and Sai jointly deliver advanced immunology assay services -- spanning high-sensitivity multiplex cytokine profiling and custom panel development -- powered by the EYRA platform installed at Sai's Boston site. The initiative is designed to significantly accelerate access to next-generation immune profiling capabilities for biopharma and biotech organisations working across immuno-oncology, vaccines, inflammation, and cellular therapy.

As part of the collaboration, Mabtech and Sai Life Sciences will engage in joint business development activities targeting US-based biopharma and biotech companies, with a particular focus on programmes in immuno-oncology, vaccine immunogenicity, and inflammation. The partnership also includes a co-branded thought leadership programme, encompassing case studies, white papers, and scientific presentations at key immunology conferences.